Notable approaches to their detection in GBMs include a telomerase promoter-based assay by Macarthur et al. in 11 glioma patients [32], antibodies directed against glial fibrillary acidic protein (GFAP), together with the detection of EGFR gene amplifications in 141 GBM patients by Muller et al. [33] and a microfluidic device by Sullivan and colleagues in 33 GBM patients [34]. The gene discussed is GFAP; the disease is central nervous system cancer.